SG158856A1 - Controlled release compositions based on block copolymers - Google Patents

Controlled release compositions based on block copolymers

Info

Publication number
SG158856A1
SG158856A1 SG201000063-6A SG2010000636A SG158856A1 SG 158856 A1 SG158856 A1 SG 158856A1 SG 2010000636 A SG2010000636 A SG 2010000636A SG 158856 A1 SG158856 A1 SG 158856A1
Authority
SG
Singapore
Prior art keywords
composition
controlled release
block copolymers
pharmaceutical
compositions based
Prior art date
Application number
SG201000063-6A
Other languages
English (en)
Inventor
Anne Chantal Bechet
Dijkhuizen-Radersma Riemke Van
Martin Stigter
Jeroen Mattijs Bezemer
Original Assignee
Biolex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc
Publication of SG158856A1 publication Critical patent/SG158856A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG201000063-6A 2005-01-07 2006-01-06 Controlled release compositions based on block copolymers SG158856A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05075043A EP1679065A1 (en) 2005-01-07 2005-01-07 Controlled release compositions for interferon based on PEGT/PBT block copolymers

Publications (1)

Publication Number Publication Date
SG158856A1 true SG158856A1 (en) 2010-02-26

Family

ID=34937981

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201000063-6A SG158856A1 (en) 2005-01-07 2006-01-06 Controlled release compositions based on block copolymers

Country Status (24)

Country Link
US (3) US7736674B2 (he)
EP (4) EP1679065A1 (he)
JP (2) JP2008526837A (he)
KR (2) KR20070118225A (he)
CN (2) CN101791396A (he)
AT (1) ATE431134T1 (he)
AU (2) AU2006213168B2 (he)
BR (1) BRPI0606514A2 (he)
CA (1) CA2594434A1 (he)
CY (1) CY1109297T1 (he)
DE (1) DE602006006797D1 (he)
DK (1) DK1843749T3 (he)
ES (1) ES2327267T3 (he)
HK (1) HK1152644A1 (he)
HR (1) HRP20090434T1 (he)
IL (2) IL184431A (he)
MX (1) MX2007008293A (he)
PL (1) PL1843749T3 (he)
PT (1) PT1843749E (he)
RS (1) RS51129B (he)
RU (2) RU2409348C2 (he)
SG (1) SG158856A1 (he)
SI (1) SI1843749T1 (he)
WO (1) WO2006085747A1 (he)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
JP2010534681A (ja) * 2007-07-25 2010-11-11 バイオレックス・セラピューティクス インコーポレイテッド 放出制御インターフェロン製剤及びそれを使用するｈｃｖ感染の治療
EP2055299A1 (en) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
JP5733981B2 (ja) 2007-10-23 2015-06-10 コーニンクレッカ フィリップス エヌ ヴェ ポリマー微粒子を調製する方法及びデバイス
WO2010001325A2 (en) * 2008-06-30 2010-01-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
EP2403537A1 (en) 2009-03-05 2012-01-11 Ascendis Pharma A/S Interferon alpha carrier prodrugs
EP2694040A4 (en) * 2011-03-25 2014-09-03 Selecta Biosciences Inc SYNTHETIC NANOVECTORS WITH OSMOTICALLY MEDIATED RELEASE
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP3197436B1 (en) 2014-09-24 2022-03-09 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2021009040A1 (en) 2019-07-12 2021-01-21 Basf Se Process for producing microparticles laden with a volatile organic active

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (he) * 1962-07-11
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ES2187506T3 (es) 1992-04-24 2003-06-16 Chienna Bv Dispositivos para la prevencion de adhesiones de tejidos.
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
ATE161716T1 (de) * 1992-08-07 1998-01-15 Takeda Chemical Industries Ltd Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2238829A1 (en) 1995-11-30 1997-06-05 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
DK0990440T3 (da) 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
ES2205481T3 (es) * 1997-04-17 2004-05-01 Amgen Inc. Microparticulas biodegradables para la liberacion sostenida de farmacos terapeuticos.
MY118835A (en) 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
IL134901A0 (en) * 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
CA2360232A1 (en) * 1999-01-12 2000-07-20 Tamio Mizukami Telomerase inhibitors
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
MXPA02000461A (es) 1999-07-15 2002-07-30 Takeda Chemical Industries Ltd Composiciones de liberacion prolongada, metodos para producir las mismas y uso de estas.
EP1090928B1 (en) 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) * 2000-11-13 2010-10-06 日東電工株式会社 多孔質ポリイミドの製造方法及び多孔質ポリイミド
CZ20031559A3 (cs) 2000-12-13 2004-03-17 Merckle Gmbh Mikročástice se zlepšeným profilem uvolňování a způsob jejich výroby
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
RU2191012C1 (ru) 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
AU2002350622B2 (en) 2001-10-24 2006-09-14 Pari Pharma Gmbh Kit for the preparation of a pharmaceutical composition
AU2002343681B2 (en) * 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
WO2003055470A1 (fr) 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
KR101139112B1 (ko) 2002-06-25 2012-04-30 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
CA2532302C (en) 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
ES2375802T3 (es) 2004-04-15 2012-03-06 Alkermes Pharma Ireland Limited Dispositivo de liberación sostenida a base de pol�?mero.
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers

Also Published As

Publication number Publication date
AU2010224413A1 (en) 2010-10-14
WO2006085747A1 (en) 2006-08-17
CY1109297T1 (el) 2014-07-02
US20080008733A1 (en) 2008-01-10
DK1843749T3 (da) 2009-09-07
SI1843749T1 (sl) 2009-10-31
EP2266535B1 (en) 2013-03-06
US20090226532A1 (en) 2009-09-10
IL184431A (he) 2012-03-29
CN101791396A (zh) 2010-08-04
US20100074868A1 (en) 2010-03-25
RU2010138739A (ru) 2012-03-27
JP2008526837A (ja) 2008-07-24
AU2006213168B2 (en) 2011-09-15
EP2266535A2 (en) 2010-12-29
EP2266535A3 (en) 2011-06-15
ES2327267T3 (es) 2009-10-27
KR20100109983A (ko) 2010-10-11
ATE431134T1 (de) 2009-05-15
BRPI0606514A2 (pt) 2010-01-19
RS51129B (sr) 2010-10-31
HK1152644A1 (en) 2012-03-09
PL1843749T3 (pl) 2009-10-30
JP2011016836A (ja) 2011-01-27
US7867518B2 (en) 2011-01-11
CN101137349B (zh) 2013-01-02
US8163307B2 (en) 2012-04-24
KR20070118225A (ko) 2007-12-14
US7736674B2 (en) 2010-06-15
RU2007130090A (ru) 2009-02-20
IL184431A0 (en) 2007-10-31
MX2007008293A (es) 2007-12-07
AU2010224413B2 (en) 2012-03-22
JP4887542B2 (ja) 2012-02-29
HRP20090434T1 (hr) 2009-09-30
EP1886668B1 (en) 2012-11-14
CA2594434A1 (en) 2006-08-17
CN101137349A (zh) 2008-03-05
PT1843749E (pt) 2009-08-17
IL208175A0 (en) 2010-12-30
KR101354521B1 (ko) 2014-01-22
RU2409348C2 (ru) 2011-01-20
EP1886668A1 (en) 2008-02-13
EP1843749A1 (en) 2007-10-17
DE602006006797D1 (de) 2009-06-25
EP1679065A1 (en) 2006-07-12
EP1843749B1 (en) 2009-05-13
AU2006213168A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
SG158856A1 (en) Controlled release compositions based on block copolymers
WO2007050387A3 (en) Keratin bioceramic compositions
SI3404102T1 (sl) Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti
WO2006105172A3 (en) Peg-polyacetal and peg-polyacetal-poe graft copolymers and pharmaceutical compositions
SG156650A1 (en) Thienopyrimidines useful as aurora kinase inhibitors
AU1387002A (en) New cross-linked derivatives of hyaluronic acid
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
AU9036598A (en) Methods and compositions to prevent formation of adhesions in biological tissues
EP3187153A3 (en) Bearing implant
EP2266590A3 (en) Active agent delivery sytems and methods for protecting and administering active agents
EP2360180A3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
WO2004087229A3 (en) Bone cement compositions
WO2007053512A3 (en) Novel protein transduction domains and uses therefor
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2006107946A3 (en) Bone cement compositions and the like comprising an rnaiii-inhibiting peptide
WO2004041158A3 (en) Rifalazil compositions and therapeutic regimens
WO2007034490A3 (en) Diastereomeric peptides for modulating t cell immunity
AU2003251729A1 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
SI1976538T1 (sl) Farmacevtska formulacija za zdravljenje osteoartritisa, ki vsebuje klodronsko kislino in hialuronsko kislino
AU2003208197A1 (en) Use of soluble fgl2 as an immunosuppressant
ATE208627T1 (de) Orale zusammensetzungen mit niedrigdosierten zytotoxischen proteinen
RU2006144370A (ru) Способ профилактики послеоперационного остеомиелита